Measles future or investigational therapies: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
===Current Investigations=== | |||
===Future Needs=== | |||
==References== | ==References== | ||
Revision as of 05:50, 25 June 2014
|
Measles Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Measles future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Measles future or investigational therapies |
|
Risk calculators and risk factors for Measles future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Despite the impact of primary prevention with vaccination in the incidence of measles there is still no specific antiviral treatment for the disease once it develops. Most developing countries are still severely affected by the high incidence of this conditions, in part due to the absence of an adequate vaccination system. Therefore, it is essential the role of research in developing a more adequate approach to the disease, once it is established. Also, the development of easier and less expensive ways of bringing the vaccine to populations in developing countries would greatly contribute to a potential eradication of measles.